Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/sage/tnf-alpha-antagonists-and-neurologic-side-effects-a-literature-review-k6touDd4WD
References (25)
-
(2003)
Humira Package Insert . 19 . Remicaide Package Insert . 20 . Enbrel Package Insert -
M. Sánchez, G. Domínguez, J. Marchante (2010)
[Demyelinating encephalomyelitis associated with treatment with adalimumab].Neurologia, 25 2
-
S. Block (2002)
Hidden hazards and practical problems: comment on the 2002 update of the American College of Rheumatology Guidelines for the Management of Rheumatoid Arthritis.Arthritis and rheumatism, 46 11
-
A. Adebajo, C. Mitchell (2007)
Patient's ethnicity and use of therapies in rheumatoid arthritis.The Journal of rheumatology, 34 1
-
M. Bechtel, C. Sanders, A. Bechtel (2009)
Neurological complications of biologic therapy in psoriasis: a review.The Journal of clinical and aesthetic dermatology, 2 11
-
M. Cisternas, M. Gutiérrez, S. Jacobelli (2002)
Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al.Arthritis and rheumatism, 46 11
-
T. Ruiz-Jimeno, A. Carvajal, C. Mata, E. Aurrecoechea (2006)
multiple sclerosis treated with infliximab . Demyelinating disease in a patient with psoriatic arthritis and family history of -
Alice Kim, N. Saffra (2012)
A case report of adalimumab-associated optic neuritisJournal of Ophthalmic Inflammation and Infection, 2
-
L. Bensouda-Grimaldi, D. Mulleman, J. Valat, E. Autret‐Leca (2007)
Adalimumab-associated multiple sclerosis.The Journal of rheumatology, 34 1
-
Sean Sukal, L. Nadiminti, R. Granstein (2006)
Etanercept and demyelinating disease in a patient with psoriasis.Journal of the American Academy of Dermatology, 54 1
-
M. Sánchez, G. Domínguez, J. Marchante (2010)
Encefalomielitis desmielinizante asociada al tratamiento con adalimumabNeurologia, 25
-
E. Taoufik, V. Tseveleki, S. Chu, Theodore Tselios, M. Karin, H. Lassmann, David Szymkowski, L. Probert (2011)
Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kappaB.Brain : a journal of neurology, 134 Pt 9
-
B. Arnason (2011)
Tumour Necrosis Factor Neutralization in MS: A Cautionary Tale.International MS journal, 17 2
-
M. Hamon, G. Nicolas, F. Devière, F. Letournel, F. Dubas (2007)
Neuropathie démyélinisante au cours d’un traitement par anti-TNF alpha et revue de la littératureRevue Neurologique, 163
-
A. Kruglov, Vicky Lampropoulou, S. Fillatreau, S. Nedospasov (2011)
Pathogenic and Protective Functions of TNF in Neuroinflammation Are Defined by Its Expression in T Lymphocytes and Myeloid CellsThe Journal of Immunology, 187
-
W. Ibrahim, M. Hammoudah, N. Akhtar, H. Al-Hail, D. Deleu (2007)
Central nervous system demyelination associated with etanercept in a 51 years old womanThe Libyan Journal of Medicine, 2
-
H. Freeman, B. Flak (2005)
Demyelination-like syndrome in Crohn's disease after infliximab therapy.Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 19 5
-
M. Hamon, G. Nicolas, F. Devière, F. Letournel, F. Dubas (2007)
[Demyelinating neuropathy during anti-TNF alpha treatment with a review of the literature].Revue neurologique, 163 12
-
J. Stübgen (2008)
Tumor necrosis factor‐α antagonists and neuropathyMuscle & Nerve, 37
-
S. Davis, Robert Johnson, J. Pendleton (2008)
Demyelinating disease associated with use of etanercept in patients with seronegative spondyloarthropathies.The Journal of rheumatology, 35 7
-
A. Solomon, R. Spain, M. Kruer, D. Bourdette (2011)
Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitorsMultiple Sclerosis Journal, 17
-
R. Fleischmann, S. Baumgartner, M. Weisman, Thomas Liu, B. White, P. Peloso (2005)
Long term safety of etanercept in elderly subjects with rheumatic diseasesAnnals of the Rheumatic Diseases, 65
-
C. Rodríguez-Escalera, J. Belzunegui, L. López-Domínguez, C. González, M. Figueroa (2005)
Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy.Rheumatology, 44 1
-
P. Lozeron, C. Denier, C. Lacroix, D. Adams (2009)
Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.Archives of neurology, 66 4
-
J. Kur-Zalewska, J. Swarowska-Knap, W. Tłustochowicz (2008)
Neurological disorders with demyelinating brain white matter lesions in a patient with rheumatoid arthritis treated with etanercept.Polskie Archiwum Medycyny Wewnetrznej, 118 4
- Publisher
- SAGE
- Copyright
- © 2013 National Psoriasis Foundation
- ISSN
- 1089-3504
- eISSN
- 1557-3168
- DOI
- 10.1177/247553031319a00202
- Publisher site
- See Article on Publisher Site
Abstract
Although several tumor necrosis factor-alpha antagonists (TNF-α therapy) have been approved by the FDA for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis, dermatologists had concerns regarding their potential for the rare induction or exacerbation of demyelinating processes. Whether TNF-α therapy induces new-onset demyelination or exacerbates pre-existing latent multiple sclerosis is not fully understood. TNF-α antagonists are immunosuppressive agents used to treat various chronic inflammatory diseases, including rheumatoid arthritis (RA), Crohn's disease, ankylosing spondylitis (AS), psoriasis, and psoriatic arthritis. Demyelinating symptoms have been observed in many of the diseases for which TNF-α therapy is approved. In addition, neurological disorders have been reported during treatment with all TNF-α antagonists, most commonly etanercept. Based on the data, it seems most reasonable to exercise caution in patients with established demyelinating disease and to immediately discontinue therapy and pursue diagnostic tests in any patient with suspected demyelination.
Journal
Journal of Psoriasis and Psoriatic Arthritis – SAGE
Published: Jun 1, 2013